PepGen Faces Investor Suit Over Muscular Dystrophy Drug

By Sydney Price · June 11, 2025, 6:35 PM EDT

Clinical-stage biotech company PepGen Inc. has been hit with a proposed shareholder class action alleging it misled investors about the efficacy and commercial prospects of its muscular dystrophy drug, causing share...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

Karam v. PepGen Inc. et al

Case Number

Court

New York Eastern

Nature of Suit

Securities/Commodities

Date Filed

June 09, 2025

Recent Articles By Sydney

June 03, 2025
Rosen, Pomerantz To Lead Seattle Biotech Class Action
May 28, 2025
Mallinckrodt Investors Get Initial OK For $5.5M Settlement
May 27, 2025
Bluebird Bio Beats Investor Suit Over FDA Cancer Warning
May 20, 2025
Cancer Drug Co. Beats Investor Suit Over FDA Rejection
May 16, 2025
Biotech Co. Hit With Investor Suits Over Cancer Drug Launch
May 14, 2025
Integra Brass Face Investor Suit Over FDA Compliance Lapses
May 06, 2025
Trump Orders FDA To Speed Up Drug Plant Approvals
April 23, 2025
GoodRx Beats Investor Suit Over Kroger-Linked Biz
April 22, 2025
Tivity Health Denied Win In Suit Over Nutrisystem Buy
April 17, 2025
Zenas BioPharma Faces Investor Suit Over Post-IPO Plunge